The ethyl acetate extract of Schefflera kwangsiensis ameliorates oxaliplatin-induced peripheral neuropathic pain via SERCA2b

Abstract

Oxaliplatin (OXA) is a widely used chemotherapeutic agent whose clinical utility is limited by OXA-induced peripheral neuropathy (OIPN). Sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) transports Ca²⁺ from the cytoplasm into the endoplasmic reticulum (ER), thereby maintaining intracellular Ca²⁺ homeostasis. Schefflera kwangsiensis Merr. ex H.L. Li (SKM) is traditionally used to treat neuropathic pain conditions such as trigeminal neuralgia and sciatica, and its active component Schekwanglupaside C has been identified as a potent SERCA activator. In this study, an OIPN mouse model was established by intraperitoneal administration of OXA (4 mg·kg⁻¹) on days 1, 2, 8, 9, 15, and 16. SERCA2b mRNA and protein expression in dorsal root ganglia (DRG) were evaluated by quantitative polymerase chain reaction (qPCR) and immunofluorescence. Mechanical allodynia was assessed using the Von Frey test. DRG neuronal excitability was examined by whole-cell current-clamp recordings, whereas oxidative stress and neuronal apoptosis/necrosis were assessed using the reactive oxygen species (ROS)-sensitive probe 2',7'-dichlorofluorescin diacetate (H₂DCFDA) and fluorescein isothiocyanate (FITC)/propidium iodide (PI) dual staining. This study identifies SERCA2b as a novel therapeutic target for OIPN. We observed that SERCA2b mRNA and protein levels were significantly downregulated during OIPN progression. Treatment with the SERCA agonist CDN1163 (CDN), the ethyl acetate extract of SKM (SKM.Ext), or duloxetine (DLX) attenuated neuronal pathology, restored DRG neuron soma diameter, and reduced the expression of pro-inflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor α (TNF-α). Pre-incubation of DRG neurons with CDN1163 or SKM.Ext for 1 h significantly attenuated OXA-induced hyperexcitability and reduced the abnormal increase in voltage-gated sodium channel (VGSC) current density. Inhibition of oxidative stress with N-acetyl-L-cysteine (NAC) significantly restored SERCA expression in OIPN, indicating that oxidative stress downregulates SERCA2b in DRG. Collectively, these findings demonstrate that activation of SERCA2b by CDN1163 or Schefflera kwangsiensis extract enhances SERCA2b expression, reduces DRG neuronal sensitization, and alleviates OIPN. This work supports SERCA2b as a novel therapeutic target for OXA-induced neuropathy and expands the potential clinical analgesic indications of Schefflera kwangsiensis.

Keywords

Oxaliplatin-induced peripheral neuropathy / Neuropathic pain / Sarco/endoplasmic reticulum Ca²⁺-ATPase / Schefflera kwangsiensis

Funding

This work was supported by the Natural Science Foundation of Jiangsu Province of China (No. BK20221054), the National Natural Science Foundation of China (Nos. 82204653, 82373929, and 82100585), the Major Program of Jiangsu Provincial Administration for Market Regulation (No. KJ2024014), “Double First-Class” University Project (No. CPU2022QZ30), the Open Fund Project of State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture (No. SKL2024Z0104), and Tibet Autonomous Region Science and Technology Plan Project Key Project (No. XZ202301ZY0014G).

Supporting information

Supporting information for this work can be obtained by contacting the corresponding authors via E-mail.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. Ca-Cancer J Clin. 2024; 74(1):12-49. https://doi.org/10.3322/caac.21820.

[2] Iragorri N, de Oliveira C, Fitzgerald N, et al. The out-of-pocket cost burden of cancer care—a systematic literature review. Curr Oncol. 2021; 28(2):1216-1248. https://doi.org/10.3390/curroncol28020117.

[3] Sałat K, Furgała A, Malikowska‐Racia N. Searching for analgesic drug candidates alleviating oxaliplatin‐induced cold hypersensitivity in mice. Chem Biol Drug Des. 2019; 93(6):1061-1072. https://doi.org/10.1111/cbdd.13507.

[4] Renn CL, Carozzi VA, Rhee P, et al. Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain. 2011;7:1744-8069-1747-1729. https://doi.org/10.1186/1744-8069-7-29.

[5] Dahl R, Bezprozvanny I. SERCA pump as a novel therapeutic target for treating neurodegenerative disorders. Biochem Bioph Res Commun. 2024; 734:150748. https://doi.org/10.1016/j.bbrc.2024.150748.

[6] Duncan C, Mueller S, Simon E, et al. Painful nerve injury decreases sarco-endoplasmic reticulum Ca²⁺-ATPase activity in axotomized sensory neurons. Neuroscience, 2013; 231:247-257. https://doi.org/10.1016/j.neuroscience.2012.11.055.

[7] Verkhratsky A, Fernyhough P. Mitochondrial malfunction and Ca²⁺ dyshomeostasis drive neuronal pathology in diabetes. Cell Calcium. 2008; 44(1):112-122. https://doi.org/10.1016/j.ceca.2007.11.010.

[8] Li SH, Zhao F, Tang QL, et al. Sarco/endoplasmic reticulum Ca²⁺‐ATPase (SERCA2b) mediates oxidation‐induced endoplasmic reticulum stress to regulate neuropathic pain. Brit J Pharmacol. 2022; 179(9):2016-2036. https://doi.org/10.1111/bph.15744.

[9] Wang Y, Khan FA, Siddiqui M, et al. The genus Schefflera: a review of traditional uses, phytochemistry and pharmacology. J Ethnopharmacol. 2021; 279:113675. https://doi.org/10.1016/j.jep.2020.113675.

[10] Yang GL, Wang Y, Yu YY, et al. Schekwanglupaside C, a new lupane saponin from Schefflera kwangsiensis, is a potent activator of sarcoplasmic reticulum Ca²⁺-ATPase. Fitoterapia. 2019; 137:104150. https://doi.org/10.1016/j.fitote.2019.04.005.

[11] Wang Y, Zhang CL, Liu YF, et al. Two new lupane saponins from Schefflera kwangsiensis. hytochem Lett. 2016; 18:19-22. https://doi.org/10.1016/j.phytol.2016.08.021.

[12] Kilkenny C, Browne W, Cuthill IC, et al. Animal research: reporting in vivo experiments—the ARRIVE guidelines. Brit J Pharmacol. 2011; 31(4):991-993. https://doi.org/10.1038/jcbfm.2010.220.

[13] McGrath JC, McLachlan EM, Zeller R. Transparency in research involving animals: The Basel Declaration and new principles for reporting research in BJP manuscripts. Brit J Pharmacol. 2015; 172(10):2427-2432. https://doi.org/10.1111/bph.12956.

[14] Zhao F, Tang QL, Xu J, et al. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain. Toxins. 2019; 11(4):229. https://doi.org/10.3390/toxins11040229.

[15] Wang RK, Yang TY, Feng Q, et al. Integration of network pharmacology and proteomics to elucidate the mechanism and targets of traditional Chinese medicine Biyuan Tongqiao granule against allergic rhinitis in an ovalbumin-induced mice model. J Ethnopharmacol. 2024; 318:116816. https://doi.org/10.1016/j.jep.2023.116816.

[16] Sakurai M, Egashira N, Kawashiri T, et al. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain. 2009; 147(1-3):165-174. https://doi.org/10.1016/j.pain.2009.09.003.

[17] Yamamoto S, Ono H, Kume K, et al. Oxaliplatin treatment changes the function of sensory nerves in rats. J Pharmacol. Sci. 2016; 130(4):189-193. https://doi.org/10.1016/j.jphs.2015.12.004.

[18] Li L, Shao JP, Wang JS, et al.MiR-30b-5p attenuates oxaliplatin-induced peripheral neuropathic pain through the voltage-gated sodium channel Na_v1. 6 in rats. Neuropharmacology. 2019; 153:111-120. https://doi.org/10.1016/j.neuropharm.2019.04.024.

[19] Zhao F, Wang SY, Li Y, et al. Surfactant cocamide monoethanolamide causes eye irritation by activating nociceptor TRPV1 channels. Brit J Pharmacol. 2021; 178(17):3448-3462. https://doi.org/10.1111/bph.15491.

[20] Wang Y, Sui YT, Lian AB, et al. PBX1 attenuates hair follicle-derived mesenchymal stem cell senescence and apoptosis by alleviating reactive oxygen species-mediated DNA damage instead of enhancing DNA damage repair. Fron Cell Dev Biol. 2021; 9:739868. https://doi.org/10.3389/fcell.2021.739868.

[21] Zimmermann M, Meyer N. Annexin V/7-AAD staining in keratinocytes. Methods Mol Biol. 2011; 740:57-63. https://doi.org/10.1007/978-1-61779-108-6_8.

[22] Dahl R. A new target for Parkinson’s disease: small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats. Bioorgan Med Chem. 2017; 25(1):53-57. https://doi.org/10.1016/j.bmc.2016.10.008.

[23] Aromolaran KA, Goldstein PA. Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy: cause and effect? Mol Pain. 2017; 13:1744806917714693. https://doi.org/10.1177/1744806917714693.

[24] Frenz CT, Hansen A, Dupuis ND, et al.Na_v1. 5 sodium channel window currents contribute to spontaneous firing in olfactory sensory neurons. J Neurophysiol. 2014; 112(5):1091-1104. https://doi.org/10.1152/jn.00154.2014.

[25] Wu B, Su XL, Zhang WT, et al. Oxaliplatin depolarizes the IB4-dorsal root ganglion neurons to drive the development of neuropathic pain through TRPM8 in mice. Front Mol Neurosci. 2021; 14:690858. https://doi.org/10.3389/fnmol.2021.690858.

[26] Kwak AW, Park JW, Lee SO, et al. Isolinderalactone sensitizes oxaliplatin-resistance colorectal cancer cells through JNK/p38 MAPK signaling pathways. Phytomedicine. 2022; 105:154383. https://doi.org/10.1016/j.phymed.2022.154383.

[27] Nguyen HT, Noriega Polo C, Wiederkehr A, et al. CDN1163, an activator of sarco/endoplasmic reticulum Ca²⁺ ATPase, up‐regulates mitochondrial functions and protects against lipotoxicity in pancreatic β‐cells. Brit J Pharmacol. 2023; 180(21):2762-2776. https://doi.org/10.1111/bph.16160.

[28] Du J, Sudlow LC, Luzhansky ID, et al. DRG explant model: elucidating mechanisms of oxaliplatin-induced peripheral neuropathy and identifying potential therapeutic targets. bioRxiv. 2023;10.05.560580. https://doi.org/10.1101/2023.10.05.560580.

[29] Lin YT, Chen JC.Dorsal root ganglia isolation and primary culture to study neurotransmitter release. J Vis Exp. 2018;(140): 57569. https://doi.org/10.3791/57569.

[30] Mattar M, Umutoni F, Hassan MA, et al. Chemotherapy-induced peripheral neuropathy: a recent update on pathophysiology and treatment. Life. 2024; 14(8):991. https://doi.org/10.3390/life14080991.

[31] Pan XL, Xiao XT, Ding YL, et al. Neurological adverse events associated with oxaliplatin: a pharmacovigilance analysis based on FDA adverse event reporting system. Front Pharmacol. 2024; 15:1431579. https://doi.org/10.3389/fphar.2024.1431579.

[32] Kang LM, Tian YY, Xu SL. et al. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment. J Neurol. 2021; 268:3269-3282. https://doi.org/10.1007/s00415-020-09942-w.

[33] Kanat O, Ertas H, Caner B. Platinum-induced neurotoxicity: a review of possible mechanisms. World J Clin Oncol. 2017; 8(4):329. https://doi.org/10.5306/wjco.v8.i4.329.

[34] Jamieson SMF, Liu J, Connor B, et al. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemoth Pharm. 2005; 56:391-399. https://doi.org/10.1007/s00280-004-0953-4.

[35] Avallone A, Bimonte S, Cardone C, et al. Pathophysiology and therapeutic perspectives for chemotherapy-induced peripheral neuropathy. Anticancer Res. 2022; 42(10):4667-4678. https://doi.org/10.21873/anticanres.15971.

[36] Basso M, Modoni A, Spada D, et al. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemoth Pharm. 2011; 67:1179-1187. https://doi.org/10.1007/s00280-010-1466-y.

[37] Shi HS, Lai K, Yin XL, et al. Ca²⁺-dependent recruitment of voltage-gated sodium channels underlies bilirubin-induced overexcitation and neurotoxicity. Cell Death Dis. 2019; 10(10):774. https://doi.org/10.1038/s41419-019-1979-1.

[38] Broomand A, Jerremalm E, Yachnin J, et al. Oxaliplatin neurotoxicity-no general ion channel surface-charge effect. J Negat Results Biomed. 2009; 8:1-8. https://doi.org/10.1186/1477-5751-8-2.

[39] Pinet C, Le Grand B, John GW, et al. Thrombin facilitation of voltage-gated sodium channel activation in human cardiomyocytes: implications for ischemic sodium loading. Circulation. 2002; 106(16):2098-2103. https://doi.org/10.1161/01.CIR.0000034510.64828.96.

[40] King M, Joseph S, Albert A, et al. Use of amifostine for cytoprotection during radiation therapy: a review. Oncology. 2020; 98(2):61-80. https://doi.org/10.1159/000502979.

[41] Yang Y, Zhao B, Gao XJ, et al. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development. J Exp Clin Cancer Res. 2021; 40:1-25. https://doi.org/10.1186/s13046-021-02141-z.

[42] Kawashiri T, Mine K, Kobayashi D, et al. Therapeutic agents for oxaliplatin-induced peripheral neuropathy; experimental and clinical evidence. Int J Mol Sci. 2021; 22(3):1393. https://doi.org/10.3390/ijms22031393.

[43] Chen C, Xu JL, Gu ZC, et al. Danggui Sini decoction alleviates oxaliplatin-induced peripheral neuropathy by regulating gut microbiota and potentially relieving neuroinflammation related metabolic disorder. Chin Med-Uk. 2024; 19(1):58. https://doi.org/10.1186/s13020-024-00929-7.

[44] Durand JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Onco. 2012; 23(1):200-205. https://doi.org/10.1093/annonc/mdr045.

[45] Zimmerman C, Atherton PJ, Pachman D, et al. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer. 2016; 24:1071-1078. https://doi.org/10.1007/s00520-015-2876-5.

[46] Sordi G, Goti A, Young HS, et al. Stimulation of Ca²⁺‐ATPase transport activity by a small‐molecule drug. ChemMedChem. 2021; 16(21):3293-3299. https://doi.org/10.1002/cmdc.202100350.

[47] Russell I, Michalek JE, Flechas JD, et al. Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. J Rheumatol. 1995; 22(5):953-958.

[48] Li JS, Su SL, Xu Z, et al. Potential roles of gut microbiota and microbial metabolites in chronic inflammatory pain and the mechanisms of therapy drugs. Ther Adv Chronic Dis. 2022; 13:20406223221091177. https://doi.org/10.1177/20406223221091177.

[49] Shakya A, Singh GK, Chatterjee SS, et al. Role of fumaric acid in anti-inflammatory and analgesic activities of a Fumaria indica extracts. J Intercult Ethnopharmacol. 2014; 3(4):173. https://doi.org/10.5455/jice.20140912021115.

[50] Guan S, Feng H, Song B, et al. Salidroside attenuates LPS-induced pro-inflammatory cytokine responses and improves survival in murine endotoxemia. Int Immunopharmacol. 2011; 11(12):2194-2199. https://doi.org/10.1016/j.intimp.2011.09.018.

[51] Liu J, Ma W, Zang CH, et al. Salidroside inhibits NLRP3 inflammasome activation and apoptosis in microglia induced by cerebral ischemia/reperfusion injury by inhibiting the TLR4/NF-κB signaling pathway. Ann Transl Med. 2021; 9(22):1694. https://doi.org/10.21037/atm-21-5752.

[52] Lim EJ, Kang HJ, Jung HJ, et al. Anti-Inflammatory, anti-angiogenic and anti-nociceptive activities of 4-hydroxybenzaldehyde. Biomol Ther. 2008; 16(3):231-236. https://doi.org/10.4062/biomolther.2008.16.3.231.

[53] Carullo G, Cappello AR, Frattaruolo L, et al. Quercetin and derivatives: useful tools in inflammation and pain management. Future Med Chem. 2017; 9(1):79-93. https://doi.org/10.4155/fmc-2016-0186.

[54] Azevedo MI, Pereira AF, Nogueira RB, et al. The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatin-induced chronic painful peripheral neuropathy. Mol Pain. 2013; 9:53. https://doi.org/10.1186/1744-8069-9-53.

[55] Kafali M, Finos MA, Tsoupras A. Vanillin and its derivatives: a critical review of their anti-inflammatory, anti-Infective, wound-healing, neuroprotective, and anti-cancer health-promoting benefits. Nutraceuticals. 2024; 4(4):522-561. https://doi.org/10.3390/nutraceuticals4040030.

[56] Lee JH, Choi JH, Kim J, et al. Syringaresinol alleviates oxaliplatin-induced neuropathic pain symptoms by inhibiting the inflammatory responses of spinal microglia. Molecules. 2022; 27(23):8138. https://doi.org/10.3390/molecules27238138.

[57] Baek SH, Park T, Kang MG, et al. Anti-inflammatory activity and ROS regulation effect of sinapaldehyde in LPS-stimulated RAW 264.7 macrophages. Molecules. 2020; 25(18):4089. https://doi.org/10.3390/molecules25184089.

[58] Ganaie MA, Jan BL, Khan TH, et al. The protective effect of naringenin on oxaliplatin-induced genotoxicity in mice. Chem Pharm Bull. 2019; 67(5):433-438. https://doi.org/10.1248/cpb.c18-00809.

[59] Wang CQ, Wang Y, Wang WJ, et al. New oleanane saponins from Schefflera kwangsiensis. Phytochem Lett. 2014; 10:268-271. https://doi.org/10.1016/j.phytol.2014.10.010.

[60] Wang Y, Liu YF, Zhang CL, et al. Four new triterpenoid saponins isolated from Schefflera kwangsiensis and their inhibitory activities against FBPase1. Phytochem Lett. 2016; 15:204-209. https://doi.org/10.1016/j.phytol.2016.01.007.

[61] Wang Y, Liang D, Khan FA, et al.Chemical constituents from Schefflera leucantha R. Vig. (Araliaceae).. Biochem Syst Ecol. 2020; 91:104076. https://doi.org/10.1016/j.bse.2020.104076.

[62] Shen PL, Wang JJ. Quality analysis research of Chinese peach leaf. J Hubei Univ Chin Med. 2012; 14(2):33-34. https://doi.org/10.3969/j.issn.1008-987x.2012.01.13.

[63] Zhang L, Wang Y, Yu DQ. Simultaneous quantification of six major triterpenoid saponins in Schefflera kwangsiensis using high-performance liquid chromatography coupled to orbitrap mass spectrometry. Nat Prod Res. 2015; 29(14):1350-1357. https://doi.org/10.1080/14786419.2015.1025397.

[64] Yang T, Li XS, Zheng L, et al. Chemical Constituents of Schefflera leucantha (II). J Chin Med Mater. 2022; 45(9):2118-2121. https://doi.org/10.13863/j.issn1001-4454.2022.09.016.

[65] Luo Y, Yan T, Gong ZP, et al. Research progress on chemical composition, pharmacological action and quality control of Schefflera arboricola. Guizhou Agric Sci. 2020; 48(12):109-113. https://doi.org/10.3969/j.issn.1001-3601.2020.12.023.

[66] Deng FS, Ma FX. Determination of the contents of two active components in Schefflera kwangsiensis Merr. Ex L. by RP-HPLC Method. Jiangxi J Chin Tradit Med. 2012; 43(12):59-61.

[67] Yang T, Li XS, Huang Y, et al. Chemical constituents from the stems and leafy stems of Schefflera leucantha. J Chin Med Mater. 2021; 44(7):1631-1635. https://doi.org/10.13863/j.issn1001-4454.2021.07.016.

[68] Yang X, Xu NZ, Fu WF, et al. Quality analysis of Schefflera kwangsiensis Merr. based on HPLC fingerprinting combined with chemometrics. Herald Med. 2024; 43(2):267-273. https://doi.org/10.3870/j.issn.1004-0781.2024.02.019.